Histomorphometric evidence of deleterious effect of aluminum on osteoblasts.
Bone histomorphometry was performed in 26 hemodialyzed patients to study the relation between the dynamic parameters of bone formation and aluminum deposition. Patients were divided into two groups according to whether bone formation rate at tissue level (Svft) was above or below normal: 0.089 mu 3/mu 2 per day. The 12 patients who constituted group II, defined by a Svft less than 0.089 mu 3/mu 2 per day, had markedly decreased extent of double-labeled surfaces (m = 1.3 +/- 6.5%), and these were absent in 8 of 12 patients. Osteomalacia, defined by decreased formation with increased mean osteoid thickness (greater than 15 micron), was present in only 3 of 12 patients in group II. The 14 patients who constituted group I, defined by a Svft greater than 0.089 mu 3/mu 2 per day, had both increased total labeled surfaces and mineralization rate. Osteomalacia was present in none of the group I patients. In trabecular bone, group II patients had increased stainable aluminum deposition, compared to group I patients, whether estimated as total stainable aluminum (2.16 +/- 1.34 vs 0.17 +/- 0.28 mm/mm2) or stainable percent of trabecular surfaces (42 +/- 19 vs 4 +/- 5%). This last parameter was inversely related to osteoblastic surfaces (r = -0.49, n = 26, P less than 0.01) and total labeled surfaces (r = -0.72, n = 26, P less than 0.01). Therefore, massive aluminum deposition was not invariably associated with impaired mineralization but with decreased formation due to decreased extent of active formation surfaces. In the group I patients, moderate aluminum deposition was not associated with the mineralization arrest observed in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
de Vernejoul
M C
MC
Belenguer
R
R
Halkidou
H
H
Buisine
A
A
Bielakoff
J
J
Miravet
L
L
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000009:adverse effects* / Q000032:analysis; D001706:Biopsy; D001846:Bone Development; D001842:Bone and Bones / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D010006:Osteoblasts / Q000032:analysis / Q000187:drug effects* / Q000473:pathology; D010018:Osteomalacia / Q000139:chemically induced* / Q000473:pathology; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D013194:Staining and Labeling
D010281:Parathyroid Hormone; D000535:Aluminum